13.09.2010 • News • Novo Nordisk • Insulin

Novo Nordisk Says to Double China Research and Development Centre

Denmark's Novo Nordisk , the world's biggest maker of insulin, said on Monday it would double the size of its research and development centre in Beijing to 200 employees by 2015.
"The expansion will mainly be dedicated to a new diabetes research unit," Novo Nordisk said in a statement. The company did not give any financial details

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Top-Feature